supercritical fluid technology
Adjust Font Size: Decrease Increase

Micell's intellectual property portfolio contains more than 40 patents or patent applications with over 6,000 patent claims that only partially reflect our expertise in a variety of processes employing supercriticals across a wide range of materials, configurations, products, and manufacturing systems. This broad portfolio reflects the enabling of 'limus drug performance with sustained-release kinetics, enhanced stability, increased yields, and rapid product development.

Micell's intellectual property portfolio includes patents and patent applications either owned by Micell, or exclusively licensed from distinguished institutions such as Battelle Memorial Institute. Micell owns or controls intellectual property covering unique bioabsorbable drug delivery formulations and related process methods in the following biomedical applications:

  1. Controlling the morphology, distribution and drug-delivery characteristics of drugs in sustained-release coatings and drug delivery materials
  2. Coating complex medical devices with drug/polymer formulations
  3. 'Dry', low-temperature drug/polymer coating processes that maintain the structure and morphology of therapeutic agents

With its first core patent expiration years away in 2022, Micell is continuing to innovate and complement its patent portfolio.

Caution: The MiStent SES has received CE marking but is not approved in the USA or any other countries. Any other products described on this website are investigational devices that are not available for sale in any country.
Home | About Us | Therapeutic Focus | Product Pipeline | Technology | News | Terms of Use | Privacy Policy | Site Map
© 2014 Micell Technologies, Inc. All rights reserved.
"Micell", "MiStent", and "MiStent SES" are registered trademarks of Micell Technologies, Inc.